The mechanism by which 5-aminosalicylic acid (5-ASA) reduces mucosal injury
in colitis is undefined. In murine cells, 5-ASA modulates the expression o
f the inducible nitric oxide (NO) synthase, a potential mediator of colitic
injury, but its effect on the human isoform is unknown. Given the lack of
conserved regulation of iNOS expression in rodent and human systems, we sou
ght to test the effect of 5-ASA on the expression of human iNOS in cultured
enterocytes. Transformed human intestinal epithelial cells, DLD-1 and Caco
-2BBe, were stimulated by IL-1 beta and IFN-gamma and analyzed for iNOS upr
egulation and NO production in the presence of various aminosalicylates. 5-
ASA, but not 4-ASA, dose-dependently inhibited NO production by both cell l
ines [IC50 (mM) DLD-1 =4.5, Caco-2BBe =2.5]. 5-ASA also inhibited the expre
ssion of iNOS protein and mRNA and blocked cytokine-induced transcriptional
upregulation of the iNOS gene. 5-ASA (1-5 mM) had no effect on cytokine-in
duced nuclear translocation of NF-kappa B or expression of IRF-1, transacti
vating factors which regulates the human iNOS enhancer. We conclude that 5-
ASA inhibits iNOS expression and NO production at therapeutically relevant
concentrations. The inhibition occurs at the level of transcriptional activ
ation and is independent of IRE-1 and NF-kappa B. Since NO is an important
final effector of mucosal injury in inflammatory bowel disease, these findi
ngs may have implications for the clinical efficacy of 5-ASA.